Work

Abstract PS5-12-23: Herthena-breast01: a phase 1b/2, multicenter, open-label, dose-finding study to evaluate the safety and antitumor activity of patritumab deruxtecan (HER3-DXd) in HER2+ unresectable locally advanced or metastatic breast cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-12-23

Authors: S. Tolaney, C. Pinheiro, A. Sporchia, Q. Liu, K. M. Hirshfield, H. Iwata

Institutions: Harvard University, Dana-Farber Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), Nagoya City University

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129492892

Cites:

Cited by:

Related to: